447459-51-0

447459-51-0 structure

Name: SCH 336
Chemical Name: N-{(1S)-1-[4-({4-Methoxy-2-[(4-methoxyphenyl)sulfonyl]phenyl}sulfonyl)phenyl]ethyl}methanesulfonamide
CAS Number: 447459-51-0
Molecular Formula: C₂₃H₂₅NO₈S₃
Molecular Weight: 539.64
Catalog: Signaling Pathways GPCR/G Protein Cannabinoid Receptor
Create Date: 2021-01-15 17:41:51
Modify Date: 2024-01-10 19:40:54
SCH 336 is a potent, selective, inverse and orally active CB2 agonist. SCH 336 inhibits BaF3/CB2 migration. SCH 336 significantly inhibits the migration of leukocytes in vivo. SCH 336 blocks ovalbumin-induced lung eosinophilia in mice[1].

Name	N-{(1S)-1-[4-({4-Methoxy-2-[(4-methoxyphenyl)sulfonyl]phenyl}sulfonyl)phenyl]ethyl}methanesulfonamide
Synonyms	Methanesulfonamide, N-[(1S)-1-[4-[[4-methoxy-2-[(4-methoxyphenyl)sulfonyl]phenyl]sulfonyl]phenyl]ethyl]- N-{(1S)-1-[4-({4-Methoxy-2-[(4-methoxyphenyl)sulfonyl]phenyl}sulfonyl)phenyl]ethyl}methanesulfonamide

Description	SCH 336 is a potent, selective, inverse and orally active CB2 agonist. SCH 336 inhibits BaF3/CB2 migration. SCH 336 significantly inhibits the migration of leukocytes in vivo. SCH 336 blocks ovalbumin-induced lung eosinophilia in mice[1].
Related Catalog	Research Areas >> Inflammation/Immunology Signaling Pathways >> GPCR/G Protein >> Cannabinoid Receptor
Target	hCB2-R
In Vitro	SCH 336 (Sch.336) (0-10 µM) competes with [3H]CP55,940 for binding to human CB2 on Sf9 cell membranes with Ki of 1.8 nM, and decreases GTPγS binding on human CB2-containing membranes with an EC50 of 2 nM, decreases potency on CB1-containing membranes with EC50 of 200 nM[1]. SCH 336 inhibits BaF3/CB2 migration to 100 nM 2-AG with an IC50 of 34 nM[1].
In Vivo	SCH 336 (0.02, 0.2, 2.0 mg/kg; i.p.) significantly inhibits the migration of leukocytes[1]. Animal Model: Female B6D2/F1 mice (HU210)[1] Dosage: 0.02, 0.2, 2.0 mg/kg Administration: I.p. Result: Significantly inhibited the migration of leukocytes into the CCL2-soaked gel foam sponge.
References	[1]. Lunn CA, et al. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther. 2006 Feb;316(2):780-8.